Literature DB >> 19091440

Acute hepatitis B in a healthcare worker: a case report of genuine vaccination failure.

Hein J Boot1, Laurens A van der Waaij, Jurjen Schirm, Cees G M Kallenberg, Jim van Steenbergen, Bert Wolters.   

Abstract

BACKGROUND: Individuals who reach the antibody threshold level of 10IU/l against the surface protein of the hepatitis B virus (HBV) after completion of a series of hepatitis B vaccination are considered to be long-term protected against a clinically manifest HBV infection. CASE REPORT: Here we describe an acute hepatitis B infection in a patient who received five hepatitis B vaccinations. Although his initial response to vaccination was moderate, he finally reached an excellent hepatitis B surface antibody level (anti-HBs) titres of more than 1000 IU/l in response to a booster vaccination with a recombinant DNA vaccine. Nevertheless, he developed full-blown acute hepatitis due to an HBV infection 14years after this booster vaccination. A DNA analysis of the surface protein encoding region followed by phylogenetic analysis showed that our patient was infected with a normal HBV strain that is circulating among men who have sex with men. To our knowledge, this is the first report of a genuine hepatitis B vaccination failure in someone who acquired a high anti-HBs level in response to a recombinant DNA hepatitis B vaccine.
CONCLUSION: Healthcare workers whose response to the initial hepatitis B vaccination is moderate might be vulnerable to hepatitis B virus infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19091440     DOI: 10.1016/j.jhep.2008.07.040

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  7 in total

1.  Identification of occult hepatitis B virus (HBV) infection and viral antigens in healthcare workers who presented low to moderate levels of anti-HBs after HBV vaccination.

Authors:  Zohreh Borzooy; Seyed Mohammad Jazayeri; Abbass Mirshafiey; Azam Khamseh; Masoud Karkhaneh Mahmoudie; Pedram Azimzadeh; Babak Geravand; Mohammad Ali Boroumand; Mina Afshar; Vahdat Poortahmasebi; Mostafa Hosseini; Adrian Streinu-Cercel
Journal:  Germs       Date:  2015-12-02

Review 2.  Hepatitis B virus: where do we stand and what is the next step for eradication?

Authors:  Haruki Komatsu
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 3.  Prevalence of National Responsiveness to HBV Vaccine After 22 Years of Iranian Expanded Program on Immunization (EPI): A Systematic Review and Meta-Analysis Study.

Authors:  Reza Rezaee; Bahman Aghcheli; Vahdat Poortahmasebi; Mostafa Qorbani; Seyed Moayed Alavian; Seyed Mohammad Jazayeri
Journal:  Hepat Mon       Date:  2015-04-25       Impact factor: 0.660

4.  Durability of immunity by hepatitis B vaccine in Japanese health care workers depends on primary response titers and durations.

Authors:  Nori Yoshioka; Matsuo Deguchi; Hideharu Hagiya; Masanori Kagita; Hiroko Tsukamoto; Miyuki Takao; Hisao Yoshida; Norihisa Yamamoto; Yukihiro Akeda; Yoshiko Nabetani; Ikuhiro Maeda; Yoh Hidaka; Kazunori Tomono
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

Review 5.  Hepatitis B virus and its sexually transmitted infection - an update.

Authors:  Takako Inoue; Yasuhito Tanaka
Journal:  Microb Cell       Date:  2016-09-05

Review 6.  Revaccination against hepatitis B in late teenagers who received vaccination during infancy: Yes or no?

Authors:  Hong Zhao; Yi-Hua Zhou
Journal:  Hum Vaccin Immunother       Date:  2017-12-06       Impact factor: 3.452

7.  Serologic control against hepatitis B virus among dental students of the University of Granada, Spain.

Authors:  M-T Arias-Moliz; L Rojas; F Liébana-Cabanillas; C Bernal; F Castillo; A Rodríguez-Archilla; A Castillo; J Liébana
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2015-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.